Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against downside risk New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution Fund LLC (the "Alphaledger T12 Fund") as a core component of its real-world asset (RWA) investment strategy on the Solana blockchain. This strategic allocation aligns with Silo's approac

Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a comprehensive update detailing progress for lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety, and key achievements under Silo's new digital assets treasury platform launched in August 2025. Biopharmaceutical Platform: Silo i

SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) --   Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of Bitcoin under its crypto reserve strategy targeting multi-chain asset growth. "Silo's latest strategic crypto purchase signals our conviction in Bitcoin as both store of value and a hedge against general financial market volatility," said Eric Weisblum, CEO of Silo. "Overall, the four crypto investments we have made so far underscore our Company's confidence in the growing adoption and value creation opportunities available through a digital asset treasury

Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exer

SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that wil

Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\. Eric Weisblum, CEO of Silo, commented, "Fireblocks brings unmatched ex

SARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform. "Our engagement with Fireblocks is expected to ensure that our newly deployed crypto treasury platform is built with enterprise grade security and governance standards," said Silo CEO Eric Weisblum. "We believe that Fireblocks' proven institutional-grade infrastructure makes them the right pa

Strategic capital deployment advances Company's blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchases of crypto tokens under its recently announced cryptocurrency treasury strategy targeting multi-chain asset growth. The Company's acquisition of Ethereum (ETH) and Solana (SOL) tokens marks the first step toward incorporating cryptocurrency into its treasury holdings and lays the foundation for Silo's broader blockchain and real world asset (RWA)

SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disord

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

S-1 - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

424B5 - Silo Pharma, Inc. (0001514183) (Filer)

DEFA14A - Silo Pharma, Inc. (0001514183) (Filer)

DEF 14A - Silo Pharma, Inc. (0001514183) (Filer)

PRE 14A - Silo Pharma, Inc. (0001514183) (Filer)

424B5 - Silo Pharma, Inc. (0001514183) (Filer)

10-Q - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)